Oxygen Biotherapeutics Mission & Goals
News & Events
Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
• Acquired strategic assets from Phyxius Pharma, including lead candidate levosimendan; named John Kelley as CEO
• Activated sites for Phase 3 LEVO-CTS trial for levosimendan in LCOS in the U.S., with data expected in first calendar quarter of 2016
• Raised $55.0 million in net proceeds through secondary offering in March 2014
Conference call today at 8:30am ET
Tuesday, July 29, 2014 8:00 am EDT
Public Company Information:
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced financial results for the fiscal year ended April 30, 2014, and provided a corporate update. more..
The Mission of Oxygen Biotherapeutics is to develop and market specialty pharmaceutical products that address unmet needs of critical care patients, their health care providers, and the hospitals who treat these patients.